CHAPEL HILL, N.C., Apr 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of product candidates for the treatment of migraine, today announced its plan to conduct a conference call following the release of financial results for the first quarter ended March 31, 2002. The company will release earnings before the market opens on Thursday, April 25, 2002. John R. Plachetka, Pharm.D., POZEN's chairman, president and chief executive officer, and Matthew E. Czajkowski, chief financial officer, will host the conference call the same day at 11:00 a.m. Eastern time.

The conference call will be simulcast live on the Internet, and can be accessed by logging on to www.ccbn.com . A replay will be available at this site, as well as on the Investor Relations section of the company's website, www.pozen.com, for seven days.

North Carolina-based POZEN Inc. is a pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. POZEN's initial focus is on developing products for migraine therapy, a global market expected to exceed $2.6 billion this year. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN."

POZEN is on the Internet at www.pozen.com .

CONTACT:
Matt Czajkowski
Chief Financial Officer, of POZEN
+1-919-913-1040
or
General Inquiries
Kathy Brunson of FRB Weber Shandwick
+1-312-640-6696